Wan, Eric Yuk Fai, Wang, Boyuan, Lee, Amanda Lauren, Zhou, Jiayi, Chui, Celine Sze Ling, Lai, Francisco Tsz Tsun, Wong, Carlos King Ho, Hung, Ivan Fan Ngai, Lau, Chak Sing, Chan, Esther Wai Yin and Wong, Ian Chi Kei (2024). Comparative Effectiveness and Safety of BNT162b2 and CoronaVac in Hong Kong: A Target Trial Emulation. International Journal of Infectious Diseases, 146 ,
Abstract
OBJECTIVES: To evaluate the difference between BNT162b2 and CoronaVac in vaccine effectiveness and safety. METHODS: This target trial emulation study included individuals aged ≥ 12 during 2022. Propensity score matching was applied to ensure group balance. The Cox proportional hazard model was used to compare the effectiveness outcomes including COVID-19 infection, severity, 28-day hospitalization and 28-day mortality after infection. Poisson regression was used for safety outcomes including 32 adverse events of special interests between groups. RESULTS: 639,818 and 1,804,388 individuals were identified for the 2-dose and 3-dose comparison, respectively. In 2-dose and 3-dose comparison, the hazard ratios (HRs) (95% confidence intervals [CI]) were 0.844 [0.833-0.856] and 0.749 [0.743-0.755] for COVID-19 infection, 0.692 [0.656-0.731] and 0.582 [0.559-0.605] for hospitalization, 0.566 [0.417-0.769] and 0.590 [0.458-0.76] for severe COVID-19, and 0.563 [0.456-0.697] and 0.457 [0.372-0.561] for mortality for BNT162b2 recipients versus CoronaVac recipients, respectively. Regarding safety, 2-dose BNT162b2 recipients had a significantly higher incidence of myocarditis (Incidence rate ratio[IRR][95% CI]: 8.999 [1.14-71.017]) versus CoronaVac recipients, but the difference was insignificant in 3-dose comparison (IRR [95% CI]: 2.000 [0.500-7.996]). CONCLUSIONS: BNT162b2 has higher effectiveness among individuals aged ≥ 12 against COVID-19-related outcomes for SARS-CoV-2 omicron compared to CoronaVac, with almost 50% lower mortality risk. (200 words).
Publication DOI: | https://doi.org/10.1016/j.ijid.2024.107149 |
---|---|
Divisions: | College of Health & Life Sciences > Aston Pharmacy School |
Funding Information: | HMRF Research on COVID-19, The Hong Kong Special Administrative Region (HKSAR) Government (Principal Investigator (WP2): EWYC; Ref No. COVID1903011); Collaborative Research Fund, University Grants Committee, the HKSAR Government (Principal Investigator: I |
Additional Information: | Copyright © 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
Uncontrolled Keywords: | COVID-19,CoronaVac,BNT162b2 |
Publication ISSN: | 1878-3511 |
Data Access Statement: | Data are not available as the data custodians (the HA and the DH of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or nongovernmental organizations may apply for access to data through the HA’s data-sharing portal (https://www3.ha.org.hk/data). |
Last Modified: | 15 Aug 2024 07:10 |
Date Deposited: | 05 Aug 2024 09:20 |
Full Text Link: | |
Related URLs: |
https://www.sci ... 201971224002200
(Publisher URL) http://www.scop ... tnerID=8YFLogxK (Scopus URL) |
PURE Output Type: | Article |
Published Date: | 2024-09 |
Published Online Date: | 2024-06-21 |
Accepted Date: | 2024-06-18 |
Authors: |
Wan, Eric Yuk Fai
Wang, Boyuan Lee, Amanda Lauren Zhou, Jiayi Chui, Celine Sze Ling Lai, Francisco Tsz Tsun Wong, Carlos King Ho Hung, Ivan Fan Ngai Lau, Chak Sing Chan, Esther Wai Yin Wong, Ian Chi Kei ( ![]() |
Download
Version: Published Version
License: Creative Commons Attribution Non-commercial No Derivatives
| Preview